Betablokker-påvirkninger på inflammatoriske og nevrale responser på stress
2. november 2026 oppdatert av: University of North Carolina, Chapel Hill
The purpose of this study is to map the neural and molecular mechanisms underlying psychological stress-induced changes in inflammation which could reveal new targets for intervention to reduce the risk of cardiovascular disease.
Studieoversikt
Status
Rekruttering
Forhold
Intervensjon / Behandling
Detaljert beskrivelse
The proposed work will conduct a mechanistic clinical trial utilizing the non-selective beta-adrenergic receptor blocker propranolol to examine the role of beta-adrenergic signaling in shaping neural and inflammatory responses to stress. The investigators will focus on beta-adrenergic signaling given seminal pre-clinical work showing that this molecular pathway is an important driver of stress-related increases in inflammation, and initial human neuroimaging work showing that beta-blockade leads to changes in neural responses to negative stimuli. Here, the investigators will bring these two previously disparate lines of work together to determine how experimentally blocking one critical stress-signaling pathway shapes neural activity and inflammatory responses to stress. In doing so, the investigators will be advancing knowledge by mapping mechanisms (i.e., beta-adrenergic signaling), offering methodological improvements (i.e., moving beyond correlation to using pharmacological manipulations to provide causal evidence), and identifying intervention targets (i.e., the neurocognitive systems that shift activity/connectivity in response to beta-blockade). In sum, the work proposed herein is significant because it will address the mechanisms by which one critical risk factor, psychological stress, may ultimately lead to cardiovascular disease via inflammation. The proposed study also offers significant methodological improvements over past work by using neuroimaging to identify neurocognitive pathways, and pharmacology to provide causal experimental evidence to move us beyond correlation. Finally, this project is significant because it could provide insight into novel targets for future interventions.
Studietype
Intervensjonell
Registrering (Antatt)
120
Fase
- Fase 4
Kontakter og plasseringer
Denne delen inneholder kontaktinformasjon for de som utfører studien, og informasjon om hvor denne studien blir utført.
Studiekontakt
- Navn: Keely A Muscatell, PhD
- Telefonnummer: 9164957661
- E-post: kmuscatell@unc.edu
Studer Kontakt Backup
- Navn: Jonathan Bunting, BS
- Telefonnummer: 9164957661
- E-post: jonb@unc.edu
Studiesteder
-
-
North Carolina
-
Chapel Hill, North Carolina, Forente stater, 27514
- Rekruttering
- Social Neuroscience and Health Laboratory
-
Ta kontakt med:
- Keely A Muscatell, PhD
- Telefonnummer: 916-495-7661
- E-post: kmuscatell@unc.edu
-
Underetterforsker:
- Jessica R Cohen, PhD
-
Underetterforsker:
- Kristen A Lindquist, PhD
-
Underetterforsker:
- Zev Nakamura, MD
-
-
Deltakelseskriterier
Forskere ser etter personer som passer til en bestemt beskrivelse, kalt kvalifikasjonskriterier. Noen eksempler på disse kriteriene er en persons generelle helsetilstand eller tidligere behandlinger.
Kvalifikasjonskriterier
Alder som er kvalifisert for studier
18 år til 30 år (Voksen)
Tar imot friske frivillige
Ja
Kjønn som er kvalifisert for studier
Alle
Beskrivelse
Inclusion Criteria:
- Ages 18-30 years
- Right-handed
- Fluent in English reading, writing, and speaking at least at a 10th grade level
- Body mass index (BMI) less than or equal to 35 kg/m^2
Exclusion Criteria:
Assessed as screening, reassessed at Session I:
- Non-removeable metal devices/implants/objects in the body
- Severe claustrophobia (assessed by self-report)
- Currently pregnant
- Left-handed
- Body mass index (BMI) greater than 35 kg/m^2
- History of fainting spells or any heart condition
- History of or present low resting heart rate (< 60 BPM) and/or low blood pressure (systolic blood pressure < 80mmHg)
- Self-reported physical illnesses: diabetes, cardiovascular diseases, high blood pressure, inflammatory bowel diseases, rheumatoid arthritis, asthma, autoimmune disease, Crohn's disease, ulcerative colitis, lupus
- Any self-reported diagnosed mental illness
- Current use of prescription medications (except hormonal contraceptives)
- Current or recent regular nicotine/tobacco use (cigarettes, e-cigarettes, vape, chewing tobacco, nicotine gum)
- Current regular (daily or almost daily) recreational drug use = 4 or more times per week
Instructed against during Session I, reassessed at Session II:
- Received any vaccine within the past two weeks
- Severe sleep disturbance (3-4 hours of sleep loss) the night before Session II
- Vigorous physical activity on the day of Session II
- Acute illness or allergy symptoms on the day of Session II
- Usage of over-the-counter medications on the day of Session II
- Usage of recreational drugs within 48 hours of Session II
- Usage of alcohol on the day of Session II
Studieplan
Denne delen gir detaljer om studieplanen, inkludert hvordan studien er utformet og hva studien måler.
Hvordan er studiet utformet?
Designdetaljer
- Primært formål: Grunnvitenskap
- Tildeling: Randomisert
- Intervensjonsmodell: Parallell tildeling
- Masking: Trippel
Våpen og intervensjoner
Deltakergruppe / Arm |
Intervensjon / Behandling |
|---|---|
|
Eksperimentell: Propranolol
Propranolol tablet, 40mg, one-time, orally |
Tablet encapsulated to visually look identical to the placebo.
Andre navn:
|
|
Placebo komparator: Placebo
Encapsulated placebo tablet |
Encapsulated sugar pill to visually look identical to the experimental condition.
Andre navn:
|
Hva måler studien?
Primære resultatmål
Resultatmål |
Tiltaksbeskrivelse |
Tidsramme |
|---|---|---|
|
Change in levels of pro-inflammatory cytokine interleukin-6 in response to social stress
Tidsramme: Post-drug baseline to 90-minutes post-stress task (T-90)
|
Blood plasma will be analyzed for levels of pro-inflammatory cytokine interleukin-6 (IL-6), from baseline, a baseline after drug administration, a sample 90-minutes after the stress task (T-90) measured in pg/mL. The timeline was determined on meta-analytic work showing changes in the inflammatory cytokine IL-6 are largest at 90 minutes post-stress. |
Post-drug baseline to 90-minutes post-stress task (T-90)
|
|
Change in levels of inflammatory gene expression in response to social stress
Tidsramme: Post-drug baseline to 30-minutes post-stress task (T-30)
|
Whole blood samples will be collected in PaxGene tubes and analyzed for changes in inflammatory gene expression from baseline, a baseline after drug administration, and 30-minutes after the stress task (T-30), measured in gene transcript counts per million. The timeline is based on the Principal Investigator's work showing that changes in pro-inflammatory gene expression are observed 30-minutes post-stress. |
Post-drug baseline to 30-minutes post-stress task (T-30)
|
Samarbeidspartnere og etterforskere
Det er her du vil finne personer og organisasjoner som er involvert i denne studien.
Samarbeidspartnere
Etterforskere
- Hovedetterforsker: Keely Muscatell, PhD, University of North Carolina, Chapel Hill
Publikasjoner og nyttige lenker
Den som er ansvarlig for å legge inn informasjon om studien leverer frivillig disse publikasjonene. Disse kan handle om alt relatert til studiet.
Generelle publikasjoner
- Kroenke K, Spitzer RL, Williams JB. The PHQ-9: validity of a brief depression severity measure. J Gen Intern Med. 2001 Sep;16(9):606-13. doi: 10.1046/j.1525-1497.2001.016009606.x.
- Virani SS, Alonso A, Benjamin EJ, Bittencourt MS, Callaway CW, Carson AP, Chamberlain AM, Chang AR, Cheng S, Delling FN, Djousse L, Elkind MSV, Ferguson JF, Fornage M, Khan SS, Kissela BM, Knutson KL, Kwan TW, Lackland DT, Lewis TT, Lichtman JH, Longenecker CT, Loop MS, Lutsey PL, Martin SS, Matsushita K, Moran AE, Mussolino ME, Perak AM, Rosamond WD, Roth GA, Sampson UKA, Satou GM, Schroeder EB, Shah SH, Shay CM, Spartano NL, Stokes A, Tirschwell DL, VanWagner LB, Tsao CW; American Heart Association Council on Epidemiology and Prevention Statistics Committee and Stroke Statistics Subcommittee. Heart Disease and Stroke Statistics-2020 Update: A Report From the American Heart Association. Circulation. 2020 Mar 3;141(9):e139-e596. doi: 10.1161/CIR.0000000000000757. Epub 2020 Jan 29.
- Ridker PM, Hennekens CH, Buring JE, Rifai N. C-reactive protein and other markers of inflammation in the prediction of cardiovascular disease in women. N Engl J Med. 2000 Mar 23;342(12):836-43. doi: 10.1056/NEJM200003233421202.
- Dickerson SS, Kemeny ME. Acute stressors and cortisol responses: a theoretical integration and synthesis of laboratory research. Psychol Bull. 2004 May;130(3):355-91. doi: 10.1037/0033-2909.130.3.355.
- Steptoe A, Hamer M, Chida Y. The effects of acute psychological stress on circulating inflammatory factors in humans: a review and meta-analysis. Brain Behav Immun. 2007 Oct;21(7):901-12. doi: 10.1016/j.bbi.2007.03.011. Epub 2007 May 1.
- Sporns O. Graph theory methods: applications in brain networks. Dialogues Clin Neurosci. 2018 Jun;20(2):111-121. doi: 10.31887/DCNS.2018.20.2/osporns.
- Kemeny ME. Psychobiological responses to social threat: evolution of a psychological model in psychoneuroimmunology. Brain Behav Immun. 2009 Jan;23(1):1-9. doi: 10.1016/j.bbi.2008.08.008. Epub 2008 Sep 10.
- Muscatell KA, Dedovic K, Slavich GM, Jarcho MR, Breen EC, Bower JE, Irwin MR, Eisenberger NI. Greater amygdala activity and dorsomedial prefrontal-amygdala coupling are associated with enhanced inflammatory responses to stress. Brain Behav Immun. 2015 Jan;43:46-53. doi: 10.1016/j.bbi.2014.06.201. Epub 2014 Jul 9.
- Slavich GM, Way BM, Eisenberger NI, Taylor SE. Neural sensitivity to social rejection is associated with inflammatory responses to social stress. Proc Natl Acad Sci U S A. 2010 Aug 17;107(33):14817-22. doi: 10.1073/pnas.1009164107. Epub 2010 Aug 2.
- Muscatell KA, Moieni M, Inagaki TK, Dutcher JM, Jevtic I, Breen EC, Irwin MR, Eisenberger NI. Exposure to an inflammatory challenge enhances neural sensitivity to negative and positive social feedback. Brain Behav Immun. 2016 Oct;57:21-29. doi: 10.1016/j.bbi.2016.03.022. Epub 2016 Mar 28.
- McEwen BS, Gianaros PJ. Central role of the brain in stress and adaptation: links to socioeconomic status, health, and disease. Ann N Y Acad Sci. 2010 Feb;1186:190-222. doi: 10.1111/j.1749-6632.2009.05331.x.
- Benschop RJ, Nieuwenhuis EE, Tromp EA, Godaert GL, Ballieux RE, van Doornen LJ. Effects of beta-adrenergic blockade on immunologic and cardiovascular changes induced by mental stress. Circulation. 1994 Feb;89(2):762-9. doi: 10.1161/01.cir.89.2.762.
- Rohleder N. Stimulation of systemic low-grade inflammation by psychosocial stress. Psychosom Med. 2014 Apr;76(3):181-9. doi: 10.1097/PSY.0000000000000049.
- van Gool J, van Vugt H, Helle M, Aarden LA. The relation among stress, adrenalin, interleukin 6 and acute phase proteins in the rat. Clin Immunol Immunopathol. 1990 Nov;57(2):200-10. doi: 10.1016/0090-1229(90)90034-n.
- Mehta NK, Abrams LR, Myrskyla M. US life expectancy stalls due to cardiovascular disease, not drug deaths. Proc Natl Acad Sci U S A. 2020 Mar 31;117(13):6998-7000. doi: 10.1073/pnas.1920391117. Epub 2020 Mar 16.
- Lagraauw HM, Kuiper J, Bot I. Acute and chronic psychological stress as risk factors for cardiovascular disease: Insights gained from epidemiological, clinical and experimental studies. Brain Behav Immun. 2015 Nov;50:18-30. doi: 10.1016/j.bbi.2015.08.007. Epub 2015 Aug 6.
- Gianaros PJ, Jennings JR. Host in the machine: A neurobiological perspective on psychological stress and cardiovascular disease. Am Psychol. 2018 Nov;73(8):1031-1044. doi: 10.1037/amp0000232.
- Chida Y, Steptoe A. Greater cardiovascular responses to laboratory mental stress are associated with poor subsequent cardiovascular risk status: a meta-analysis of prospective evidence. Hypertension. 2010 Apr;55(4):1026-32. doi: 10.1161/HYPERTENSIONAHA.109.146621. Epub 2010 Mar 1.
- Ginty AT, Kraynak TE, Fisher JP, Gianaros PJ. Cardiovascular and autonomic reactivity to psychological stress: Neurophysiological substrates and links to cardiovascular disease. Auton Neurosci. 2017 Nov;207:2-9. doi: 10.1016/j.autneu.2017.03.003. Epub 2017 Mar 16.
- Hong S, Dimitrov S, Cheng T, Redwine L, Pruitt C, Mills PJ, Ziegler MG, Green JM, Shaikh F, Wilson K. Beta-adrenergic receptor mediated inflammation control by monocytes is associated with blood pressure and risk factors for cardiovascular disease. Brain Behav Immun. 2015 Nov;50:31-38. doi: 10.1016/j.bbi.2015.08.012. Epub 2015 Aug 20.
- Devereux RB, Alderman MH. Role of preclinical cardiovascular disease in the evolution from risk factor exposure to development of morbid events. Circulation. 1993 Oct;88(4 Pt 1):1444-55. doi: 10.1161/01.cir.88.4.1444.
- Black PH, Garbutt LD. Stress, inflammation and cardiovascular disease. J Psychosom Res. 2002 Jan;52(1):1-23. doi: 10.1016/s0022-3999(01)00302-6.
- Pepys MB, Hirschfield GM, Tennent GA, Gallimore JR, Kahan MC, Bellotti V, Hawkins PN, Myers RM, Smith MD, Polara A, Cobb AJ, Ley SV, Aquilina JA, Robinson CV, Sharif I, Gray GA, Sabin CA, Jenvey MC, Kolstoe SE, Thompson D, Wood SP. Targeting C-reactive protein for the treatment of cardiovascular disease. Nature. 2006 Apr 27;440(7088):1217-21. doi: 10.1038/nature04672.
- Irwin MR, Cole SW. Reciprocal regulation of the neural and innate immune systems. Nat Rev Immunol. 2011 Aug 5;11(9):625-32. doi: 10.1038/nri3042.
- Flaa A, Eide IK, Kjeldsen SE, Rostrup M. Sympathoadrenal stress reactivity is a predictor of future blood pressure: an 18-year follow-up study. Hypertension. 2008 Aug;52(2):336-41. doi: 10.1161/HYPERTENSIONAHA.108.111625. Epub 2008 Jun 23.
- Bosch JA, Berntson GG, Cacioppo JT, Dhabhar FS, Marucha PT. Acute stress evokes selective mobilization of T cells that differ in chemokine receptor expression: a potential pathway linking immunologic reactivity to cardiovascular disease. Brain Behav Immun. 2003 Aug;17(4):251-9. doi: 10.1016/s0889-1591(03)00054-0.
- Gianaros PJ, Wager TD. Brain-Body Pathways Linking Psychological Stress and Physical Health. Curr Dir Psychol Sci. 2015 Aug 1;24(4):313-321. doi: 10.1177/0963721415581476.
- Madden KS, Sanders VM, Felten DL. Catecholamine influences and sympathetic neural modulation of immune responsiveness. Annu Rev Pharmacol Toxicol. 1995;35:417-48. doi: 10.1146/annurev.pa.35.040195.002221.
- Felten DL, Felten SY, Bellinger DL, Carlson SL, Ackerman KD, Madden KS, Olschowki JA, Livnat S. Noradrenergic sympathetic neural interactions with the immune system: structure and function. Immunol Rev. 1987 Dec;100:225-60. doi: 10.1111/j.1600-065x.1987.tb00534.x. No abstract available.
- Kassam KS, Mendes WB. The effects of measuring emotion: physiological reactions to emotional situations depend on whether someone is asking. PLoS One. 2013 Jun 5;8(7):e64959. doi: 10.1371/journal.pone.0064959. Print 2013.
- Woo CW, Chang LJ, Lindquist MA, Wager TD. Building better biomarkers: brain models in translational neuroimaging. Nat Neurosci. 2017 Feb 23;20(3):365-377. doi: 10.1038/nn.4478.
- Gianaros PJ, Marsland AL, Kuan DC, Schirda BL, Jennings JR, Sheu LK, Hariri AR, Gross JJ, Manuck SB. An inflammatory pathway links atherosclerotic cardiovascular disease risk to neural activity evoked by the cognitive regulation of emotion. Biol Psychiatry. 2014 May 1;75(9):738-45. doi: 10.1016/j.biopsych.2013.10.012. Epub 2013 Oct 23.
- Poldrack RA. Can cognitive processes be inferred from neuroimaging data? Trends Cogn Sci. 2006 Feb;10(2):59-63. doi: 10.1016/j.tics.2005.12.004. Epub 2006 Jan 6.
- Fu CH, Mourao-Miranda J, Costafreda SG, Khanna A, Marquand AF, Williams SC, Brammer MJ. Pattern classification of sad facial processing: toward the development of neurobiological markers in depression. Biol Psychiatry. 2008 Apr 1;63(7):656-62. doi: 10.1016/j.biopsych.2007.08.020. Epub 2007 Oct 22.
- Doehrmann O, Ghosh SS, Polli FE, Reynolds GO, Horn F, Keshavan A, Triantafyllou C, Saygin ZM, Whitfield-Gabrieli S, Hofmann SG, Pollack M, Gabrieli JD. Predicting treatment response in social anxiety disorder from functional magnetic resonance imaging. JAMA Psychiatry. 2013 Jan;70(1):87-97. doi: 10.1001/2013.jamapsychiatry.5.
- van Oort J, Tendolkar I, Hermans EJ, Mulders PC, Beckmann CF, Schene AH, Fernandez G, van Eijndhoven PF. How the brain connects in response to acute stress: A review at the human brain systems level. Neurosci Biobehav Rev. 2017 Dec;83:281-297. doi: 10.1016/j.neubiorev.2017.10.015. Epub 2017 Oct 24.
- Henckens MJ, van der Marel K, van der Toorn A, Pillai AG, Fernandez G, Dijkhuizen RM, Joels M. Stress-induced alterations in large-scale functional networks of the rodent brain. Neuroimage. 2015 Jan 15;105:312-22. doi: 10.1016/j.neuroimage.2014.10.037. Epub 2014 Oct 22.
- Soszynski D, Kozak W, Conn CA, Rudolph K, Kluger MJ. Beta-adrenoceptor antagonists suppress elevation in body temperature and increase in plasma IL-6 in rats exposed to open field. Neuroendocrinology. 1996 May;63(5):459-67. doi: 10.1159/000127072.
- Powell ND, Sloan EK, Bailey MT, Arevalo JM, Miller GE, Chen E, Kobor MS, Reader BF, Sheridan JF, Cole SW. Social stress up-regulates inflammatory gene expression in the leukocyte transcriptome via beta-adrenergic induction of myelopoiesis. Proc Natl Acad Sci U S A. 2013 Oct 8;110(41):16574-9. doi: 10.1073/pnas.1310655110. Epub 2013 Sep 23.
- Johnson JD, Campisi J, Sharkey CM, Kennedy SL, Nickerson M, Greenwood BN, Fleshner M. Catecholamines mediate stress-induced increases in peripheral and central inflammatory cytokines. Neuroscience. 2005;135(4):1295-307. doi: 10.1016/j.neuroscience.2005.06.090. Epub 2005 Sep 13.
- Hanke ML, Powell ND, Stiner LM, Bailey MT, Sheridan JF. Beta adrenergic blockade decreases the immunomodulatory effects of social disruption stress. Brain Behav Immun. 2012 Oct;26(7):1150-9. doi: 10.1016/j.bbi.2012.07.011. Epub 2012 Jul 24.
- Hermans EJ, van Marle HJ, Ossewaarde L, Henckens MJ, Qin S, van Kesteren MT, Schoots VC, Cousijn H, Rijpkema M, Oostenveld R, Fernandez G. Stress-related noradrenergic activity prompts large-scale neural network reconfiguration. Science. 2011 Nov 25;334(6059):1151-3. doi: 10.1126/science.1209603.
- Hurlemann R, Walter H, Rehme AK, Kukolja J, Santoro SC, Schmidt C, Schnell K, Musshoff F, Keysers C, Maier W, Kendrick KM, Onur OA. Human amygdala reactivity is diminished by the beta-noradrenergic antagonist propranolol. Psychol Med. 2010 Nov;40(11):1839-48. doi: 10.1017/S0033291709992376. Epub 2010 Jan 27.
- von Kanel R, Kudielka BM, Metzenthin P, Helfricht S, Preckel D, Haeberli A, Stutz M, Fischer JE. Aspirin, but not propranolol, attenuates the acute stress-induced increase in circulating levels of interleukin-6: a randomized, double-blind, placebo-controlled study. Brain Behav Immun. 2008 Feb;22(2):150-7. doi: 10.1016/j.bbi.2007.07.005. Epub 2007 Sep 18.
- O'Connor MF, Bower JE, Cho HJ, Creswell JD, Dimitrov S, Hamby ME, Hoyt MA, Martin JL, Robles TF, Sloan EK, Thomas KS, Irwin MR. To assess, to control, to exclude: effects of biobehavioral factors on circulating inflammatory markers. Brain Behav Immun. 2009 Oct;23(7):887-97. doi: 10.1016/j.bbi.2009.04.005. Epub 2009 Apr 21.
- Muscatell KA, Dedovic K, Slavich GM, Jarcho MR, Breen EC, Bower JE, Irwin MR, Eisenberger NI. Neural mechanisms linking social status and inflammatory responses to social stress. Soc Cogn Affect Neurosci. 2016 Jun;11(6):915-22. doi: 10.1093/scan/nsw025. Epub 2016 Mar 15.
- Eisenberger NI, Inagaki TK, Muscatell KA, Byrne Haltom KE, Leary MR. The neural sociometer: brain mechanisms underlying state self-esteem. J Cogn Neurosci. 2011 Nov;23(11):3448-55. doi: 10.1162/jocn_a_00027. Epub 2011 Mar 31.
- Dickerson SS, Gable SL, Irwin MR, Aziz N, Kemeny ME. Social-evaluative threat and proinflammatory cytokine regulation: an experimental laboratory investigation. Psychol Sci. 2009 Oct;20(10):1237-44. doi: 10.1111/j.1467-9280.2009.02437.x. Epub 2009 Sep 14.
- Wager TD, Waugh CE, Lindquist M, Noll DC, Fredrickson BL, Taylor SF. Brain mediators of cardiovascular responses to social threat: part I: Reciprocal dorsal and ventral sub-regions of the medial prefrontal cortex and heart-rate reactivity. Neuroimage. 2009 Sep;47(3):821-35. doi: 10.1016/j.neuroimage.2009.05.043. Epub 2009 May 22.
- Dickerson SS, Mycek PJ, Zaldivar F. Negative social evaluation, but not mere social presence, elicits cortisol responses to a laboratory stressor task. Health Psychol. 2008 Jan;27(1):116-21. doi: 10.1037/0278-6133.27.1.116.
- Marsland AL, Walsh C, Lockwood K, John-Henderson NA. The effects of acute psychological stress on circulating and stimulated inflammatory markers: A systematic review and meta-analysis. Brain Behav Immun. 2017 Aug;64:208-219. doi: 10.1016/j.bbi.2017.01.011. Epub 2017 Jan 12.
- Jolink TA, Fendinger NJ, Alvarez GM, Feldman MJ, Gaudier-Diaz MM, Muscatell KA. Inflammatory reactivity to the influenza vaccine is associated with changes in automatic social behavior. Brain Behav Immun. 2022 Jan;99:339-349. doi: 10.1016/j.bbi.2021.10.019. Epub 2021 Nov 5.
- Fredrickson BL, Grewen KM, Coffey KA, Algoe SB, Firestine AM, Arevalo JM, Ma J, Cole SW. A functional genomic perspective on human well-being. Proc Natl Acad Sci U S A. 2013 Aug 13;110(33):13684-9. doi: 10.1073/pnas.1305419110. Epub 2013 Jul 29.
- Dawkins L, Corcoran O. Acute electronic cigarette use: nicotine delivery and subjective effects in regular users. Psychopharmacology (Berl). 2014 Jan;231(2):401-7. doi: 10.1007/s00213-013-3249-8. Epub 2013 Aug 27.
- Cosme D, Zeithamova D, Stice E, Berkman ET. Multivariate neural signatures for health neuroscience: assessing spontaneous regulation during food choice. Soc Cogn Affect Neurosci. 2020 Nov 10;15(10):1120-1134. doi: 10.1093/scan/nsaa002.
- Steptoe A, Ronaldson A, Kostich K, Lazzarino AI, Urbanova L, Carvalho LA. The effect of beta-adrenergic blockade on inflammatory and cardiovascular responses to acute mental stress. Brain Behav Immun. 2018 May;70:369-375. doi: 10.1016/j.bbi.2018.03.027. Epub 2018 Mar 26.
- Gianaros PJ, Sheu LK, Uyar F, Koushik J, Jennings JR, Wager TD, Singh A, Verstynen TD. A Brain Phenotype for Stressor-Evoked Blood Pressure Reactivity. J Am Heart Assoc. 2017 Aug 23;6(9):e006053. doi: 10.1161/JAHA.117.006053.
- Fredrickson BL, Grewen KM, Algoe SB, Firestine AM, Arevalo JM, Ma J, Cole SW. Psychological well-being and the human conserved transcriptional response to adversity. PLoS One. 2015 Mar 26;10(3):e0121839. doi: 10.1371/journal.pone.0121839. eCollection 2015.
Studierekorddatoer
Disse datoene sporer fremdriften for innsending av studieposter og sammendragsresultater til ClinicalTrials.gov. Studieposter og rapporterte resultater gjennomgås av National Library of Medicine (NLM) for å sikre at de oppfyller spesifikke kvalitetskontrollstandarder før de legges ut på det offentlige nettstedet.
Studer hoveddatoer
Studiestart (Faktiske)
1. mai 2024
Primær fullføring (Antatt)
1. februar 2027
Studiet fullført (Antatt)
1. februar 2027
Datoer for studieregistrering
Først innsendt
31. januar 2024
Først innsendt som oppfylte QC-kriteriene
8. februar 2024
Først lagt ut (Faktiske)
16. februar 2024
Oppdateringer av studieposter
Sist oppdatering lagt ut (Faktiske)
5. november 2026
Siste oppdatering sendt inn som oppfylte QC-kriteriene
2. november 2026
Sist bekreftet
1. november 2026
Mer informasjon
Begreper knyttet til denne studien
Nøkkelord
Ytterligere relevante MeSH-vilkår
- Patologiske prosesser
- Patologiske tilstander, tegn og symptomer
- Kardiovaskulære sykdommer
- Betennelse
- Organiske kjemikalier
- Hydrokarboner
- Hydrokarboner, syklisk
- Karbohydrater
- Naftalener
- Polysykliske aromatiske hydrokarboner
- Hydrokarboner, aromatisk
- Polysykliske forbindelser
- Aminer
- Alkoholer
- Fenoksypropanolaminer
- Propanolaminer
- Aminoalkoholer
- Propanoler
- Propranolol
- Sukker
Andre studie-ID-numre
- 23-2768
- 1R01HL157422-01 (U.S. NIH-stipend/kontrakt)
Plan for individuelle deltakerdata (IPD)
Planlegger du å dele individuelle deltakerdata (IPD)?
NEI
Legemiddel- og utstyrsinformasjon, studiedokumenter
Studerer et amerikansk FDA-regulert medikamentprodukt
Ja
Studerer et amerikansk FDA-regulert enhetsprodukt
Nei
produkt produsert i og eksportert fra USA
Nei
Denne informasjonen ble hentet direkte fra nettstedet clinicaltrials.gov uten noen endringer. Hvis du har noen forespørsler om å endre, fjerne eller oppdatere studiedetaljene dine, vennligst kontakt register@clinicaltrials.gov. Så snart en endring er implementert på clinicaltrials.gov, vil denne også bli oppdatert automatisk på nettstedet vårt. .